SRIT wins a ₹128.9 Cr Qatar e-health order from Ooredoo — larger than its latest quarter's revenue
Ooredoo QPSC awards SRIT's Doha branch a QAR ~50 mn (₹128.93 Cr) e-health managed-services contract — against Q2 FY27 revenue of ₹104.7 Cr and a market cap of ₹812 Cr.
₹128.93 Cr
QAR ~50 million
₹126.38
Nov 13 — before the filing
SMALL-CAP
by market cap ≈ ₹812.3 Cr
₹104.70 Cr
consolidated
₹13.74 Cr
EPS ₹2.90
₹95–₹153
close −17.4% from the high
At 08:41 IST on Saturday, November 14 — before market open — SRIT India informed the BSE that it has received a new order of Qatari Riyals ~50 million, which the filing states as ₹1,289.3 million, i.e. ₹128.93 crore, from Ooredoo QPSC, described in the disclosure as a QAR ~42 billion Qatari Public Shareholding Company. The last close in this report's price data is ₹126.38 on November 13, so the market's reaction to the order is not yet visible in the series used here. What can be measured today is scale: against a market cap of roughly ₹812 crore and September-quarter consolidated revenue of ₹104.70 crore, this is a large single order for the company.
What the filing discloses
Ooredoo QPSC awards SRIT a QAR ~50 million (₹128.93 Cr) managed-services order
A Regulation 30 disclosure of a new order from Ooredoo QPSC for Managed Services for Electronic Health, and Information Systems for Pharmacy & Drug Control Departments. The filing classifies the awarding entity as international, and names the contracting parties as Ooredoo QPSC and SRIT's branch in Doha QFC, Qatar. Execution is stated in two parts: 2 years for managed services covering onboarding of hospitals, clinics, health centres and pharmacies, and 3 years for managed services of the E-Health Eco System and National Drug Control & roll-out operations.
Read:The filing states that neither the promoter, promoter group nor group companies have any interest in Ooredoo QPSC, and that the order does not fall within related-party transactions. The filing reached the exchange pre-open on November 14; the first tradable session after it is not in this report's price series, so no market reaction is recorded here.
BSE filing — awarding of order, Nov 14, 2026The disclosure is specific about the work but silent on phasing: it gives a two-year window for the onboarding component and a three-year window for the ecosystem and drug-control roll-out, and does not state how the QAR ~50 million is split across the two, or across years. Any annualised revenue estimate from this order is therefore an inference, not a filed number. What the filing does establish is the counterparty's size as the company describes it, the government-linked nature of the end departments served — Qatar's Pharmacy & Drug Control functions — and that the contract sits with SRIT's own Doha QFC branch rather than a third party.
"Order as %" = order value ÷ row value, computed from the filing and the adjusted price series. Execution spans 2–3 years per the filing — these ratios show scale, not annual revenue impact.
The arithmetic is what makes this order report-worthy: ₹128.93 crore is about 1.2× the September quarter's consolidated revenue and two-thirds of the entire first half's. Spread over the filing's two-to-three-year execution windows, the per-year contribution would be smaller — but for a company with a ₹812 crore market cap, a single international, government-linked services contract of this size changes the order-book picture in a way the next few quarterly results can be checked against.
Q2 FY27, filed two days earlier
Q2 FY27: consolidated revenue ₹104.70 Cr, net profit ₹13.74 Cr
The board, at its meeting of November 12 (concluded 7:33 PM IST), approved unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. Consolidated: revenue ₹104.70 Cr, pre-tax profit ₹18.89 Cr, net profit ₹13.74 Cr, EPS ₹2.90, operating margin 19.69%, interest cost ₹3.83 Cr. The June quarter, for comparison, had consolidated revenue of ₹87.81 Cr and net profit of ₹6.81 Cr.
Read:Quarter-on-quarter, consolidated revenue grew 19.2% and net profit roughly doubled (+101.9%). Management commentary on the half year was filed separately at 00:42 IST on November 14; the order disclosure followed the same morning.
BSE filing — Q2 FY27 board meeting outcome, Nov 12, 2026The tape around the results is worth stating precisely. On November 12 the stock closed at ₹133.00, up 7.9% on 2.27 million shares — a move that happened before the results reached the exchange at 9:45 PM that evening, and so cannot be read as a reaction to them. The next session, November 13, the first in which the results could be traded, the stock closed 5.0% lower at ₹126.38 on 2.98 million shares — the heaviest volume in the sixty-session window. A quarter with 19% sequential revenue growth and a doubled profit met a falling close; whether the Saturday order filing changes that verdict is the first thing the next session will show.
Both ends of the 52-week range, three weeks apart
Both ends of the stock's 52-week range were set inside the window shown: the ₹153 high on October 7 and the ₹95 low on October 27 — a 38% peak-to-trough span in three weeks. From the October 27 close of ₹99.62 the stock has recovered 26.9% to ₹126.38, leaving it 17.4% below the range high and 33.0% above the range low. The recovery has come with persistent volume — six of the last ten sessions traded above half a million shares — but the series also shows how quickly this stock reprices in both directions, which is the practical meaning of the small-cap caution above.
Trading window closed for designated persons ahead of the September-quarter results.
Board approved the Q1 FY27 (June-quarter) unaudited results: consolidated revenue ₹87.81 Cr, net profit ₹6.81 Cr.
Board approved Q2 and H1 FY27 results; the outcome reached the exchange at 9:45 PM, after close.
Company intimated participation of its MD & CEO Dr. Nambiar Raghavan Madhusoodan and director Dr. Amit Oberoi in a podcast scheduled for release Nov 14.
00:42 IST: management commentary on H1 FY27 filed. 08:41 IST: the Ooredoo QPSC order disclosure. 11:16 IST: newspaper publication of the results.
The sequence is dense: the June-quarter results were approved on October 26 and the September-quarter results seventeen days later on November 12, followed within forty-eight hours by management commentary, a podcast intimation and the order disclosure. For a reader, the practical consequence is that several pieces of new information — a strong quarter, a management-outlook communication, and a large order — landed on the market in the same week, and the price series available here only captures the market's response to the first of them.
The next data points
First post-filing session
The order reached the exchange pre-open on Saturday, November 14. The first session in which it can be traded is not in this data — that close is the first measurable verdict on the order.
Execution disclosures
The filing gives a 2-year onboarding window and a 3-year ecosystem roll-out window but no phasing of the QAR ~50 million. Further Regulation 30 updates, or order-book detail in coming results, would make the revenue trajectory checkable.
H2 FY27 results
Whether revenue through the Doha QFC branch begins to show against the Q2 FY27 base of ₹104.70 Cr consolidated revenue — and whether the 19.69% operating margin holds as the contract mobilises.
What the filings establish: SRIT India has disclosed a QAR ~50 million (₹128.93 crore) managed-services order from Ooredoo QPSC for Qatar's e-health and drug-control systems, contracted through its Doha QFC branch, with stated execution windows of two and three years — on the heels of a September quarter in which consolidated revenue grew 19.2% sequentially to ₹104.70 crore and net profit roughly doubled to ₹13.74 crore.
What is not yet known matters as much: the market has not traded a single session on the order within this data, the filing does not phase the contract value across years, and the stock has already shown — with a 38% range traversed in three weeks of October — that it reprices sharply on new information. The data suggests a materially enlarged order book relative to the company's size; the execution evidence will arrive one quarterly filing at a time.
Informational and educational content only. Not investment advice.